Cancer on a PET scan typically appears as a bright spot, sometimes described as “lighting up” or “glowing,” against the dimmer background of surrounding healthy tissue. The brightness reflects how aggressively cells in that area are consuming glucose, and most cancers are hungry for it. But the picture is more nuanced than a simple bright-or-dark reading, because the scan measures metabolic activity rather than directly imaging tumors, and plenty of non-cancerous processes can glow just as brightly.
Why Cancer Lights Up
The most common PET scan used in cancer imaging relies on a radioactive sugar molecule called FDG, which stands for fluorine-18-deoxyglucose. It behaves like regular glucose in the body: cells pull it in, and it gets trapped inside them. The key difference is that FDG carries a small radioactive tag that emits signals the scanner can detect. Cancer cells tend to consume far more glucose than normal cells, a trait that has been recognized for nearly a century. After injection, FDG is taken up and phosphorylated inside cells, where it becomes trapped. The uptake is driven by glucose transporter proteins on the cell surface and by an enzyme called hexokinase, both of which are overexpressed in many tumors.1Nuclear Medicine and Biology. FDG Accumulation and Tumor Biology2PubMed Central. Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors
So on the resulting image, areas of high glucose metabolism appear as intense concentrations of radioactivity, rendered in bright colors on most display settings. Aggressive cancers with fast-dividing cells generally glow more intensely than slow-growing ones. The image is typically fused with a CT scan taken at the same time, which provides the anatomical map. The CT shows the body’s structures in gray-scale detail, while the PET overlay adds a color-coded heat map of metabolic activity. This combination is what allows doctors to pinpoint not just that something is metabolically active, but exactly where in the body it sits.
Measuring How Bright Is Bright
Radiologists do not simply eyeball whether a spot is “hot enough” to be cancer. They use a measurement called the standardized uptake value, or SUV, which quantifies how much FDG has accumulated in a given area relative to what you would expect if the tracer were evenly distributed throughout the body. An SUV of 1.0 means a region is taking up about the average amount; anything substantially above that warrants closer attention. In clinical practice, an SUV above roughly 2.5 is often considered suspicious for malignancy, though this threshold varies by cancer type and body site.3PubMed Central. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy
The peak SUV reported for a lesion, called SUVmax, is the single highest value within that spot. Different cancers produce different ranges. For example, in one study of non-small cell lung cancer, the average SUVmax was around 8.3 on an early scan and rose to about 10.2 on a delayed image taken roughly an hour later.4PubMed. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions Lymphomas tend to light up intensely as well; systemic anaplastic large cell lymphoma, for instance, is reliably FDG-avid and shows up clearly on PET regardless of its molecular subtype.5PubMed Central. Evolution of (18)F-FDG Uptake as a Pitfall of Image Diagnosis for Systemic Anaplastic Large Cell Lymphoma
SUV is also used to predict outcomes and guide treatment decisions. In hypopharyngeal cancer, for example, patients whose primary tumor had an SUVmax above 9.5 before chemoradiation were much more likely to need salvage surgery afterward, suggesting the scan’s intensity can serve as a rough gauge of treatment resistance.6PubMed Central. Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv(max)) In Laryngeal and Hypopharyngeal Cancer That said, SUV measurements carry real variability. Differences in scanner calibration, the time between injection and imaging, the patient’s blood glucose level, and even body composition all introduce bias.3PubMed Central. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy A single SUV number should never be treated as a definitive cancer diagnosis on its own.
Normal Hot Spots You Should Know About
Not everything bright on a PET scan is cancer. The brain, heart, kidneys, and bladder consistently light up in healthy people. The brain runs almost entirely on glucose, so it always appears intensely bright. The heart muscle is metabolically active. The kidneys and bladder glow because FDG is filtered and excreted through the urinary system, so the tracer naturally accumulates there. In a study of healthy subjects, mild uptake was also consistently observed in the liver, spleen, and testicular tissue, and most subjects showed some degree of colon activity. Inconsistent mild to moderate uptake appeared in the parotid glands, stomach, and lymphatic tissues.7Journal of Nuclear Medicine Technology. Prospective Evaluation of Physiologic Uptake Detected with True Whole-Body 18F-FDG PET/CT in Healthy Subjects
These normal patterns are well understood, and experienced radiologists mentally subtract them when reading a scan. The challenge arises when a cancer happens to sit in or near one of these naturally active areas, or when normal physiologic activity in the bowel creates a focal hot spot that mimics a tumor. PET-CT, which fuses the metabolic data with anatomical CT images, helps sort these out, but it does not eliminate ambiguity entirely.8Radiographics. Bowel hot spots at PET-CT9PubMed Central. Physiological uptake in FDG PET simulating disease
False Positives and False Negatives
Because FDG is a marker of glucose metabolism rather than a cancer-specific agent, anything that revs up cellular activity can mimic malignancy on a PET scan. Infections are a major culprit. Bacterial infections, tuberculosis, and fungal diseases all involve activated immune cells that consume glucose at high rates. Sarcoidosis, an inflammatory condition, does the same. Radiation pneumonitis following cancer treatment and post-surgical inflammation can also create bright spots indistinguishable from tumor recurrence.10PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases In one case report, a mycobacterial infection of the gallbladder produced FDG uptake that was interpreted as gallbladder cancer; the patient underwent surgery, and only the pathology report revealed the true diagnosis.11PubMed Central. Mycobacterial infection of the gallbladder masquerading as gallbladder cancer with a false positive pet scan
False negatives happen too, though they get less attention. Certain cancers are notoriously poor FDG accumulators. Well-differentiated neuroendocrine tumors, some mucinous cancers, renal cell carcinomas, and low-grade prostate cancers can appear faint or even invisible on a standard FDG-PET scan. Small tumors, generally below about a centimeter, may also fall below the scanner’s resolution. And occasionally, the biology is more complex than the simple “cancer cells eat glucose” model would suggest. Research in a mouse model of non-small cell lung cancer found that in fed animals, FDG accumulated primarily in the non-cancerous supporting tissue (stroma) within tumors rather than in the cancer cells themselves.12Journal of Nuclear Medicine. The Reverse Warburg Effect and 18F-FDG Uptake in Non–Small Cell Lung Cancer A549 in Mice: A Pilot Study While this was an animal study, it illustrates that the bright spot on a scan may sometimes reflect something other than cancer cell metabolism per se.
Brown Fat and Other Artifacts
One of the more surprising sources of false hot spots is brown fat. Unlike the white fat that stores energy, brown fat burns glucose to generate heat. When activated, it lights up symmetrically on PET scans, typically in the neck, shoulders, and along the spine. To an untrained eye, these symmetrical streaks of brightness could look alarming. In a retrospective analysis of over 15,000 PET/CT cases, brown fat activation was reported significantly more often in patients who were female, younger, had a lower body mass index, and had lower blood glucose levels. Cold outdoor temperatures and late-morning scan times also increased the likelihood of brown fat showing up.13PubMed Central. Factors influencing brown fat activation in FDG PET/CT: a retrospective analysis of 15,000+ cases
To minimize this artifact, imaging centers keep their waiting rooms warm and sometimes give patients a blanket before injection. Some centers also ask patients to avoid caffeine and cold exposure beforehand. Metal implants, recent contrast agents, and even tense muscles during the uptake period can all create additional artifacts. Preparation matters: patients are asked to fast for several hours before the scan and avoid strenuous exercise, because any tissue that is metabolically revved up will compete with potential tumor tissue for the tracer.
Specialized Tracers Beyond FDG
FDG is the workhorse of PET imaging, but it is not the only option. For cancers that do not consume much glucose, or where more specificity is needed, different radioactive tracers can be used that target specific proteins on the surface of cancer cells.
Prostate cancer is a prime example. Low-grade prostate tumors are often invisible on FDG-PET, but over 90% of prostate cancers overexpress a protein called prostate-specific membrane antigen, or PSMA.14PubMed Central. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer PET scans using PSMA-targeting tracers have shown superior ability to detect prostate cancer metastases, particularly in patients with biochemical recurrence after treatment or with early-stage disease.15PubMed Central. The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions On these scans, the cancer still appears as bright spots, but the glow reflects PSMA expression rather than glucose metabolism, which makes the signal far more specific to prostate cancer tissue.
Neuroendocrine tumors present a similar challenge. These slow-growing tumors frequently have low glucose metabolism, making them nearly invisible on FDG-PET. Instead, clinicians use a tracer called DOTATATE, tagged with gallium-68, which binds to somatostatin receptors commonly found on these tumors. DOTATATE PET has become the preferred imaging modality for initial diagnosis of well-differentiated neuroendocrine tumors, for selecting patients for targeted therapy, and for finding primary tumors whose location is unknown.16PubMed. Neuroendocrine Tumor Diagnosis and Management: (68)Ga-DOTATATE PET/CT In patients where an older imaging technique had produced negative or unclear results, DOTATATE PET was positive in about 87% of cases, detecting far more lesions and altering clinical management in roughly 71% of patients.17Journal of Nuclear Medicine. The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
Tracking How Treatment Is Working
Beyond initial diagnosis, PET scans play a crucial role in monitoring whether treatment is having an effect. The logic is straightforward: if a tumor responds to chemotherapy, immunotherapy, or radiation, its metabolic activity should drop. A scan performed after a few cycles of treatment can show whether the bright spot has dimmed, stayed the same, or intensified. This information often determines whether doctors continue the current regimen, switch to a different one, or proceed to surgery.
Some research has looked at whether the initial intensity of a tumor on PET can predict who will respond well. In a study of locally advanced non-small cell lung cancer patients receiving immunotherapy combined with chemotherapy, the overall response rate was about 68%. But when the researchers split patients by how quickly their tumors were taking up FDG before treatment, those with the highest metabolic rates responded about 87% of the time, compared to roughly 36% for those with lower metabolic activity.18SpringerLink (European Journal of Nuclear Medicine and Molecular Imaging). Patlak-Ki derived from ultra-high sensitivity dynamic total body [(18)F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients This is counterintuitive at first: hotter tumors responded better. The likely explanation is that highly metabolic tumors may also attract more immune attention, making them more vulnerable to immunotherapy. The finding is still being investigated, but it underscores how much information can be extracted from PET images beyond simple tumor detection.
The Theranostic Link
One of the most exciting developments in PET imaging is the concept of theranostics, which combines diagnosis and treatment using the same molecular targeting system. The idea is simple in principle: if a radioactive tracer can find cancer cells by binding to a specific protein on their surface, you can swap the imaging isotope for a therapeutic one that delivers cell-killing radiation directly to those same cells.19PubMed Central. Recent advances in theranostics and oncology PET: emerging radionuclides and targets
PSMA-targeted therapy for prostate cancer is the most established example. A diagnostic PSMA PET scan first confirms that the cancer expresses the target protein. If it does, the patient can then receive the same PSMA-binding molecule loaded with lutetium-177, a beta-emitting isotope that irradiates the tumor from within. The PET scan essentially auditions the cancer for treatment eligibility. A similar approach works with DOTATATE for neuroendocrine tumors: the diagnostic gallium-68 scan identifies the lesions, and a lutetium-177 version of the same molecule delivers the therapy. This means the appearance of cancer on a PET scan is not just diagnostic information anymore; it is a treatment-selection tool. If the tumor lights up brightly with a given tracer, that same targeting pathway can be weaponized.
Total-Body Scanners and What They Change
Conventional PET scanners image a section of the body at a time and then stitch together the images. A bed position covers roughly 15 to 25 centimeters of the body per stop, so a whole-body scan requires the bed to move through multiple positions over 20 to 30 minutes. The EXPLORER total-body PET scanner, first tested in humans in 2019, changed this equation. With an axial field of view of 194 centimeters, it can capture the entire adult body in a single acquisition, covering more than 99% of the population without moving the bed.20PubMed Central. First Human Imaging Studies with the EXPLORER Total-Body PET Scanner
The practical implications are substantial. Because the scanner collects signals from the entire body simultaneously, its sensitivity is dramatically higher. Diagnostic-quality images can be produced with very small amounts of tracer or in acquisition times of roughly a minute or less.20PubMed Central. First Human Imaging Studies with the EXPLORER Total-Body PET Scanner For patients, this could mean lower radiation exposure. For doctors, it opens the door to dynamic imaging, where you watch how the tracer distributes throughout the entire body over time rather than taking a single snapshot. Watching the flow of FDG in real time across all organs simultaneously could improve the ability to distinguish cancer from inflammation, since the kinetics of uptake differ between malignant and benign tissue even when the final brightness looks similar.
How Artificial Intelligence Is Changing Interpretation
Reading a PET scan requires pattern recognition across hundreds of image slices, accounting for normal variants, artifacts, and subtle lesions that could be easy to miss. AI systems trained on large datasets of labeled PET/CT images are increasingly being tested as tools to assist radiologists. Different FDG PET-derived imaging biomarkers, including SUVmax, metabolic tumor volume, and total lesion glycolysis, serve as inputs for these models.21PubMed Central. Applications of artificial intelligence in oncologic 18F-FDG PET/CT imaging: a systematic review Large annotated datasets, such as collections of over 1,000 FDG-PET/CT scans from patients with lymphoma, melanoma, and lung cancer alongside negative controls, provide the training material these algorithms need.22The Cancer Imaging Archive. FDG-PET-CT-Lesions
AI applications in PET imaging range from automated lesion detection and segmentation to predicting treatment response and patient outcomes. The goal is not to replace the radiologist but to flag suspicious areas, reduce the chance that a small or oddly located lesion is overlooked, and standardize measurements that currently vary between readers. Early results are promising, though the field is still working through issues of validation across different scanner types, patient populations, and institutional protocols. For patients, the practical effect over time should be faster reads, fewer ambiguous reports, and potentially earlier detection of subtle recurrences that a human eye might initially pass over.
What Patients Actually See
If you have ever looked at your own PET scan report or images, the visual presentation can vary. Most clinical images use a gray-scale or a hot-metal color scale where black represents the least activity and white or bright yellow represents the highest. Some display software uses a rainbow spectrum, with cool blues for low uptake and reds or whites for high uptake. The exact colors are cosmetic choices that differ by institution and software; they do not change the underlying data. What matters is the relative intensity: how bright a spot is compared to its surroundings and compared to known reference tissues like the liver, which is often used as an internal benchmark because its uptake is fairly consistent from person to person.
Your scan report will typically describe lesions in terms of their location, their SUVmax, and whether they appear more or less active than the background. A phrase like “intensely FDG-avid mass in the right upper lobe” means a bright spot in the lung with high glucose consumption. “Mildly FDG-avid” might describe something barely above background that could be benign. “No abnormal FDG uptake” is the phrase most patients hope to read. Understanding that the scan measures metabolic activity rather than directly photographing a tumor helps make sense of why follow-up imaging, biopsy, or correlation with other tests is sometimes needed even when a spot does light up.
When PET Scanning Became Standard
PET technology existed in research settings for decades before becoming a routine clinical tool. The critical leap came in the 1990s with the development of combined PET-CT devices. A prototype underwent clinical evaluation starting in mid-1998, and after a three-year trial period, the first commercial PET-CT scanner was installed in a clinical setting in 2001.23Europe PMC. Combined positron emission tomography-computed tomography: the historical perspective The fusion of metabolic and anatomical imaging in a single machine was what made PET practical for everyday cancer care. Before combined devices, PET images showed hot spots floating in poorly defined anatomy, making precise localization difficult. The CT component solved that problem, and adoption accelerated rapidly through the 2000s. Today, standalone PET scanners without CT are essentially obsolete in oncology.